Drugs / H3K27M-vac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04808245 | Feb 2023 → Nov 2026 expected | diffuse midline glioma, H3 K27M-mutant | German Cancer Research Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3K27M-vac | “The long peptide vaccine H3K27M-vac targeting this major histocompatibility complex class II (MHC class II)-restricted neoantigen induces mutation-specific immune responses...” PMID 37853454 ↗ Oct 2023 |
| Known as | H3K27M peptide vaccine | “The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.” NCT04808245 ↗ |
| Modality | Vaccine | “The 27mer peptide vaccine H3K27M-vac will be administered concomitantly to standard radiotherapy (RT)” PMID 37853454 ↗ Oct 2023 |